<DOC>
	<DOC>NCT01052259</DOC>
	<brief_summary>The purpose of this study to examine the efficacy and safety of cycling treatment of deoxyspergualin in renal transplant patients with biopsy-proven chronic rejection.</brief_summary>
	<brief_title>Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection</brief_title>
	<detailed_description>The primary aim of this study is to investigate the efficacy of deoxyspergualin after the completion of 6 cycles treatment. The efficacy valuables are histological findings in renal grafts, renal function, proteinuria, graft survival, anti-HLA antibody. The safety data are also evaluated in the study.</detailed_description>
	<mesh_term>Gusperimus</mesh_term>
	<criteria>Chronic rejection defined by Banff 2007 criteria Patients who have recurrent renal diseases and virusassociated renal diseases Patients who have initial WBC &lt; 4,000, neutrophil &lt; 1,000 , platelet &lt; 50,000 or Hb &lt; 8g Patients who have acute or chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic rejection</keyword>
	<keyword>Kidney</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Immunosuppressive</keyword>
</DOC>